ProMetic closes C$25.1 million bought deal offering

Date closed: 12/9/2014

Value: C$25.1 million

On December 9, 2014, ProMetic Life Sciences Inc. (ProMetic or the Corporation) closed its bought deal public offering of common shares in the capital of the Corporation (the Offering) through a syndicate of underwriters led by Canaccord Genuity Corp., and which included Paradigm Capital Inc., RBC Capital Markets and Beacon Securities Limited (collectively, the Underwriters). ProMetic issued 13,200,000 common shares of the Corporation in connection with the Offering at a price of $1.90 per share for aggregate gross proceeds of C$25,080,000. In connection with the exercise by the Underwriters of the over-allotment option, the Corporation issued an addiditional 1,980,000 common shares at a price of $1.90 per common share, for additional gross proceeds of C$3,762,000.

ProMetic, headquartered in Laval, Québec is a biopharmaceutical company.

BLG represented ProMetic with a team led by Pascal de Guise that included Yaniv Saragosti.